Linked e-resources
Details
Table of Contents
Supervisor's Foreword; Acknowledgments; Contents; 1 Research Background; 1.1 Introduction; 1.2 Synthetic Methodologies and Structures of Mesoporous Materials; 1.2.1 Formation Mechanism of Mesoporous Materials; 1.2.2 Structures of Mesoporous Materials; 1.3 Biomedical Applications of Mesoporous Materials; 1.3.1 Mesoporous Materials for Drug Loading and Sustained Release; 1.3.2 Mesoporous Materials for Controlled Drug Releasing; 1.3.3 Mesoporous Materials for Photodynamic Therapy; 1.3.4 Mesoporous Materials for Synergistic Therapy; 1.3.5 MSNs for Targeted Drug Delivery.
1.3.6 Mesoporous Materials for Theranostic Applications1.3.6.1 Magnetic Resonance Imaging (MRI); 1.3.6.2 Fluorescent Imaging; 1.3.6.3 Multi-modality Diagnostic Imaging; 1.4 The Development Trends of Mesoporous Materials; 1.5 Significance of this Thesis; References; 2 Synthesis of Hollow Mesoporous Silica Nanoparticles by Silica-Etching Chemistry for Biomedical Applications; 2.1 Introduction; 2.2 Experimental Section; 2.2.1 Synthesis of HMSNs Based on SDSE Strategy; 2.2.2 Synthesis of HMSNs by Chemical Etching in Ammonia Solution; 2.2.3 Study of the Formation Mechanism of HMSNs.
2.2.4 Synthesis of Multifunctional Rattle-Type HMSNs Based on SDSE Strategy2.2.5 Hemolytic Effect Evaluation; 2.2.6 In Vitro DOX-Loading into HMSNs; 2.2.7 MTT Evaluation of the Cytotoxicity of HMSNs and DOX-HMSNs; 2.3 Results and Discussion; 2.3.1 Synthesis and Characterization of HMSNs; 2.3.2 Synthesis of Multifunctional M@mSiO2 Nanorattles; 2.3.3 HMSNs for Anticancer Drug Delivery; 2.4 Conclusions; References; 3 Multifunctional Mesoporous Silica Nanoparticles for Theranostics of Cancer; 3.1 Introduction; 3.2 Experimental Section; 3.2.1 Synthesis of Fe3O4@mSiO2.
3.2.2 Synthesis of Gd-Si-DPTA-Au@mSiO23.2.3 Blood Compatibility of Fe3O4@mSiO2; 3.2.4 In Vitro Cytotoxicity of Fe3O4@mSiO2 Nanocapsules; 3.2.5 Drug-Loading and Anticancer Efficiency; 3.2.6 CLSM Observations of the Cell Internalization of Fe3O4@mSiO2 Nanocapsules; 3.2.7 Bio-TEM Observations; 3.2.8 In Vitro and In Vivo MR Imaging; 3.2.9 Dark-Field Microscopic Labeling of HeLa Cancer Cells; 3.3 Results and Discussion; 3.3.1 Synthesis of Characterization of Fe3O4@mSiO2; 3.3.2 Magnetic Fe3O4@mSiO2 for MRI and Anticancer Drug Delivery.
3.3.3 Synthesis of Gd-Si-DTPA-Grafted Au@mSiO2 for Biomedical Applications3.4 Conclusions; References; 4 Hollow Mesoporous Silica Nanoparticles for Ultrasound-Based Cancer Diagnosis and Therapy; 4.1 Introduction; 4.2 Experimental Section; 4.2.1 Material Synthesis; 4.2.2 In Vitro MRI Evaluation; 4.2.3 Ex Vivo Evaluation Toward the HIFU Synergistic Effect of IMNCs, PFH-IMNCs, MCNCs, and PFH-MCNCs; 4.2.4 CLSM Observation of Intracellular Uptake and Location of RITC-MCNCs.
1.3.6 Mesoporous Materials for Theranostic Applications1.3.6.1 Magnetic Resonance Imaging (MRI); 1.3.6.2 Fluorescent Imaging; 1.3.6.3 Multi-modality Diagnostic Imaging; 1.4 The Development Trends of Mesoporous Materials; 1.5 Significance of this Thesis; References; 2 Synthesis of Hollow Mesoporous Silica Nanoparticles by Silica-Etching Chemistry for Biomedical Applications; 2.1 Introduction; 2.2 Experimental Section; 2.2.1 Synthesis of HMSNs Based on SDSE Strategy; 2.2.2 Synthesis of HMSNs by Chemical Etching in Ammonia Solution; 2.2.3 Study of the Formation Mechanism of HMSNs.
2.2.4 Synthesis of Multifunctional Rattle-Type HMSNs Based on SDSE Strategy2.2.5 Hemolytic Effect Evaluation; 2.2.6 In Vitro DOX-Loading into HMSNs; 2.2.7 MTT Evaluation of the Cytotoxicity of HMSNs and DOX-HMSNs; 2.3 Results and Discussion; 2.3.1 Synthesis and Characterization of HMSNs; 2.3.2 Synthesis of Multifunctional M@mSiO2 Nanorattles; 2.3.3 HMSNs for Anticancer Drug Delivery; 2.4 Conclusions; References; 3 Multifunctional Mesoporous Silica Nanoparticles for Theranostics of Cancer; 3.1 Introduction; 3.2 Experimental Section; 3.2.1 Synthesis of Fe3O4@mSiO2.
3.2.2 Synthesis of Gd-Si-DPTA-Au@mSiO23.2.3 Blood Compatibility of Fe3O4@mSiO2; 3.2.4 In Vitro Cytotoxicity of Fe3O4@mSiO2 Nanocapsules; 3.2.5 Drug-Loading and Anticancer Efficiency; 3.2.6 CLSM Observations of the Cell Internalization of Fe3O4@mSiO2 Nanocapsules; 3.2.7 Bio-TEM Observations; 3.2.8 In Vitro and In Vivo MR Imaging; 3.2.9 Dark-Field Microscopic Labeling of HeLa Cancer Cells; 3.3 Results and Discussion; 3.3.1 Synthesis of Characterization of Fe3O4@mSiO2; 3.3.2 Magnetic Fe3O4@mSiO2 for MRI and Anticancer Drug Delivery.
3.3.3 Synthesis of Gd-Si-DTPA-Grafted Au@mSiO2 for Biomedical Applications3.4 Conclusions; References; 4 Hollow Mesoporous Silica Nanoparticles for Ultrasound-Based Cancer Diagnosis and Therapy; 4.1 Introduction; 4.2 Experimental Section; 4.2.1 Material Synthesis; 4.2.2 In Vitro MRI Evaluation; 4.2.3 Ex Vivo Evaluation Toward the HIFU Synergistic Effect of IMNCs, PFH-IMNCs, MCNCs, and PFH-MCNCs; 4.2.4 CLSM Observation of Intracellular Uptake and Location of RITC-MCNCs.